Cyclosporine formulation and Kaposi's sarcoma after renal transplantation

Transplantation

Volumn 80, Issue 6, 2005, Pages 743-748

  Cattaneo, Dario ^a   Gotti, Eliana ^a   Perico, Norberto ^a,c   Bertolini, Guido ^c   Kainer, Gad ^b   Remuzzi, Giuseppe ^a  

^a OSPEDALI RIUNITI   (Italy)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Cyclosporine; Kaposi's sarcoma; Kidney transplantation; Therapeutic drug monitoring

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

AREA UNDER THE CURVE; ARTICLE; CANCER RISK; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG FORMULATION; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KAPLAN MEIER METHOD; KAPOSI SARCOMA; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY;

CHEMISTRY, PHARMACEUTICAL; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; RETROSPECTIVE STUDIES; SARCOMA, KAPOSI; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 26644467460     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000173803.97398.31     Document Type: Article

References (31)

1. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999; 353: 1083.
2. Penn I. The changing pattern of posttransplant malignancies. Transplant Proc 1991; 23: 1101.
3. Euvrad S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681.
4. Bouwes-Banvinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia: a follow-up study. Transplantation 1996; 61: 715.
5. Harwood AR, Osoba D, Horfstader SL, et al. Kaposi's sarcoma in recipients of renal transplants. Am J Med 1979; 67: 759.
6. Qunibi A, Akhtar M, Shet K, et al. Kaposi's sarcoma: the most common tumor after renal transplantation in Saudi Arabia. Am J Med 1988; 84: 225.
7. Farge D, et al. Groupe Collaboratif de Recherche en Transplantation de L'ile de France. Kaposi's sarcoma in organ transplant recipients. Eur J Med 1993; 2: 339.
8. Penn I. Kaposi's sarcoma in transplant recipients. Transplantation 1997; 64: 669.
9. Woodle E, Hanaway M, Buell J, et al. Kaposi's sarcoma: an analysis of the US and International experiences from the Israel Penn International Transplant Tumor Registry. Transplant Proc 2001; 33: 3660.
10. Gotti E, Remuzzi G. Post-transplant Kaposi's sarcoma. J Am Soc Nephrol 1997; 9: 130.
11. Noel JC, De Thier F, Heeneman M, et al. HHV-8 is associated with recurrent Kaposi's sarcoma in a renal transplant recipients. Transpl Int 1997; 10: 81.
12. Duman S, Toz H, Asci G, et al. Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression. Nephrol Dial Transplant 2002; 17: 892.
13. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530.
14. Alvarez-Arroyo MV, Yague S, Wenger RM, et al. Cyclophilin-mediated pathways in the effect of cyclosporin A on endothelial cells. Role of vascular endothelial growth factor. Circ Res 2002; 91: 202.
15. Caramelo C, Alvarez-arroyo MA, Yague S, et al. Cyclosporin A toxicity, and more: vascular endothelial growth factor (VEGF) steps forward. Nephrol Dial Transplant 2004; 19: 285.
16. Kahan BD, Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988; 46: 631.
17. Kahan BD, Dunn J, Fitts C, et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 1995; 59: 505.
18. Gaspari F, Perico N, Pisoni R, et al. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients? Clin Transplant 1998; 12: 379.
19. Gaspari F, Anedda MF, Signorini O, et al. Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration. J Am Soc Nephrol 1997; 8: 647.
20. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research. Principles and quantitative methods. New York: Van Nostrand Reinhold, 1982.
21. Su XY, Wan LPA. Combining event rates from clinical trials: comparison of Bayesian and classical methods. Ann Pharmacother 1996; 30: 460.
22. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf 2000; 23: 101.
23. Penn I, First MR. Development and incidence of cancer following cyclosporine therapy. Transplant Proc 1986; 18: 210.
24. Campistol JM, Dalmau AG, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004; 77: 760.
25. Sanders CJ, Canninga-van Dijk MR, Borleffs JC. Kaposi's sarcoma. Lancet 2004; 364: 1549.
26. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865.
27. Montaner S, Sodhi A, Molinolo A, et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 2003; 3: 23.
28. Shin GT, Khanna A, Ding R, et al. In vivo expression of transforming growth factor beta 1 in humans: stimulation by cyclosporine. Transplantation 1998; 65: 313.
29. Prashar Y, Khanna A, Shajpal P, et al. Stimulation of transforming growth factor beta 1 transcription by cyclosporine. FEBS Lett 1995; 358: 109.
30. Welch DR, Fabra A, Nakajima M. Transforming growth factor beta stimulates mammary adenocarcinoma cells invasion and metastatic potential. Proc Natl Acad Sci 1990; 87: 7678.
31. Cattaneo D, Perico N, Remuzzi G. Generic cyclosporine formulations: more open questions than answers. Transpl Int 2005; 18: 371.